Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular Phenotyping in Predicting Response to Chemotherapy in Localized Esophageal Adenocarcinoma
NCT02392377Phase 2Terminated
- Sponsor
- Case Comprehensive Cancer Center
- Start
- Feb 2015
- Primary completion
- Dec 2015
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of carboplatin, Paclitaxel Micelles for Injection, oxaliplatin, fluorouracil, folinic acid in esophageal adenocarcinoma (EAC), sponsored by Case Comprehensive Cancer Center. Started Feb 2015; status: terminated.
02
Drugs
carboplatinPaclitaxel Micelles for Injectionoxaliplatinfluorouracilfolinic acid
03
Conditions
esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT02392377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02392377.